Wolfson N, Gavish D, Matas Z, Boaz M, Shargorodsky M
Department of Medicine, Edith Wolfson Medical Center, Tel Aviv University, Israel.
Exp Diabetes Res. 2012;2012:250621. doi: 10.1155/2012/250621. Epub 2011 Dec 27.
Adiponectin has anti-atherogenic and anti-inflammatory properties. We investigated the influence of adiponectin on glucose tolerance status, adiposity and cardiovascular risk factors (CVRFs).
Study consisted of 107 subjects: 55 with normal glucose tolerance (NGT) and 52 with impaired glucose regulation (IGR) who were divided into two groups: 24 subjects with impaired fasting glucose (IFG Group) and 28 patients with type 2 diabetes mellitus (DM Group). In additional analysis, study participants were divided into two groups, according to CVRFs: low and high risk.
Patients were evaluated for glucose, HbA1C, insulin, lipids, CRP, HOMA-IR and adiponectin.
Adiponectin was significantly higher in NGT group than in IFG (P = 0.003) and DM (P = 0.01) groups. Adiponectin was significantly, positively associated with HDL and inversely associated with glucose, HbA1c, ALT, AST, TG, HOMA-IR. Patients with higher CVRFs load have lesser adiponectin compared to patients with low cardiovascular risk P < 0.0001). Adiponectin was inversely associated with the number of risk factors (r = -0.430, P = 0.0001).
Circulating adiponectin was significantly lower in subjects with different degree of IGR compared to subjects with normal glucose homeostasis. Adiponectin was significantly lower in high risk group than low risk group and decreased concurrently with increased number of CVRFs.
脂联素具有抗动脉粥样硬化和抗炎特性。我们研究了脂联素对糖耐量状态、肥胖及心血管危险因素(CVRFs)的影响。
研究包括107名受试者:55名糖耐量正常(NGT)者和52名糖调节受损(IGR)者,后者又分为两组:24名空腹血糖受损者(IFG组)和28名2型糖尿病患者(DM组)。在额外分析中,研究参与者根据CVRFs分为两组:低风险和高风险。
对患者进行血糖、糖化血红蛋白(HbA1C)、胰岛素、血脂、C反应蛋白(CRP)、稳态模型评估胰岛素抵抗(HOMA-IR)和脂联素的评估。
NGT组的脂联素显著高于IFG组(P = 0.003)和DM组(P = 0.01)。脂联素与高密度脂蛋白(HDL)显著正相关,与血糖、HbA1c、谷丙转氨酶(ALT)、谷草转氨酶(AST)、甘油三酯(TG)、HOMA-IR呈负相关。与心血管低风险患者相比,CVRFs负荷较高的患者脂联素水平较低(P < 0.0001)。脂联素与危险因素数量呈负相关(r = -0.430,P = 0.0001)。
与糖耐量正常的受试者相比,不同程度糖调节受损的受试者循环脂联素显著降低。高风险组的脂联素显著低于低风险组,且随着CVRFs数量的增加而降低。